Tasonermin

Summary

Tasonermin (CHEMBL2107891) is an approved protein (ATC L03AX11); indicated across 2 conditions including neoplasm and sarcoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L03AX11
• Indications: 2 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107891
Name	Tasonermin
Type	Protein
Max phase	4
ATC	L03AX11

Also known as: Beromun, FK 516, FK-516, Tasonermin, Tasonermina, Tasonermine, TASONERMIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
sarcoma	4	MONDO:0005089	EFO:0000691

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00181025	PHASE2	UNKNOWN	Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs’ Girdle

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).